ArticleAging2023

Efficacy of first-line tyrosine kinase inhibitor between unresectable stage III and stage IV EGFR-mutated non-small cell lung cancer patients.

Yang Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.